期刊文献+

血清中巨噬细胞炎症蛋白水平在判断多发性骨髓瘤骨病中的临床意义 被引量:2

Clinical Significance of Level of Macrophage Inflammation Protein in Serum for the Diagnosis of Multiple Myeloma Bone Disease
下载PDF
导出
摘要 【目的】探讨多发性骨髓瘤(MM)患者血清中巨噬细胞炎症蛋白(MIP)水平与多发性骨髓瘤骨病(MBD)之间的关系。【方法】采用酶联免疫吸附法检测了42例初诊MM病人(观察组)以及25例健康体检者(对照组)外周血清中MIP-1α及MIP-1β的水平、其下游信号传导因子可溶性核转录因子-κB受体活化因子的配体(sRANKL)和骨保护素(OPG)水平、以及破骨细胞代谢指标抗酒石酸酸性磷酸酶-5b(TRAP-5b)与Ⅰ型胶原蛋白羧基末端交联肽(CTP-Ⅰ)的水平,同时根据全身X光摄片判断MM患者骨损害情况,分析MIP-1α及MIP-1β与sRANKL/OPG比值、TRAP-5b和CTP-Ⅰ及MBD之间的相关性。【结果】观察组患者血清中MIP-1α及MIP-1β中位水平为125.18 ng/mL和134.35ng/mL,均明显高于对照组(P<0.05);将观察组患者按X光结果分为有MBD组(29例)和无MBD组(13例)发现:MBD组的MIP-1α及MIP-1β水平高于无MBD组(P<0.05),且MIP-1α及MIP-1β水平与骨病分级之间均存在相关性(γ分别为0.381和0.429,P<0.05);进一步分析发现:MIP-1α及MIP-1β与sRANKL/OPG比值(γ分别为0.641和0.451,P<0.05)、TRAP-5b(γ分别为0.547和0.529,P<0.05)和CTP-Ⅰ(γ值分别为0.476和0.512,P<0.05)水平之间均存在相关性。【结论】MM患者血清中MIP-1α及MIP-1β水平不仅升高,还与MBD分级有关,它可通过调节sRANKL/OPG比值和增加破骨细胞代谢来引起MBD,所以MIP-1α及MIP-1β水平可作为判断MBD的一个较好的参考指标。 [Objective]To investigate the relationship between the level of macrophage inflammation protein (MIP) in serum oi the patients with multiple myeloma (MM) and multiple myeloma bone disease (MBD). [Method] The serum levels of MIP-la and MIP-Iβ, soluble ligand of receptor activator of nuclear factor kappaB (sRANKL) and osteoprotegerin (OPG) which are in the downstream signaling factors of MIP-Ia and MIP-1β, tartrate-resistant acid phosphatase-5b (TRAP-5b) and C-terminal telopeptide of collagen I (CTP- I ) which are indexes for metabolism of osteoelast (OC) were detected in MM patients with first diagnosed (n = 42, experimental group) and healthy persons (n = 25,control group) by enzyme-linked immunosorbent assay. X-ray was also used to determine bone damage in these patients with MM at the same time. According to these results acquired, we analyzed the correlation between the levels of MIP-la and MIP-Iβ and the ratio of sRANKL/OPG, levels of TRAP-5b and CTP- I and MBD. [Result] The levels of MIP-1 a (median value was 125.18 ng/mL ) and MIP-1β (median value was 134.35 ng/mL ) were higher than that of in the control group,respectively (P 〈 0.05). All patients in experimental group were divided into group with MBD (n = 29) and group without MBD (n = 13). We found the levels of MIP-lct and MIP-Iβ in group with MBD were higher than that in group without MBD(P 〈 0.05 ). meanwhile, we also found the levels of MIP-1 ct and MIP-1 β was closely related to the ratio of sRANKL/OPG values were0.641 and 0.451, respectively, P 〈 0.05), the level of TRAP-5b (~ values were 0.547 and 0.529, respectively, P 〈 0.05) and CTP- I (Y values were 0.476 and 0.512, respectively, P 〈 0.05). [Conclusion] The levels of MIP-la and MIP-Iβ in MM patients are not only significantly elevated but also closely related to the degree of MBD and they could increase the metabolism of OCs and result in MBD by mediating the ratio of sRANKL/OPG. Therefore, The levels of M1P-la and MIP-Iβ might be used as a better reference index for the diagnosis of MBD.
出处 《中山大学学报(医学科学版)》 CAS CSCD 北大核心 2012年第1期60-64,共5页 Journal of Sun Yat-Sen University:Medical Sciences
基金 国家自然科学基金(30670997) 广东省科技计划项目(B080703055) 中山大学附属一院优秀青年人才支持计划项目(18700108)
关键词 巨噬细胞炎症蛋白 多发性骨髓瘤骨病 核转录因子-κB 受体活化因子 骨保护素 破骨细胞 macrophage inflammation protein multiple myeloma bone disease receptor activator of nuclear factor kappa B osteoprotegerin osteoclast
  • 相关文献

参考文献10

  • 1Melton LJ 3rd,Kyle RA,Achenbach SJ,et al.Fracture risk with multiple myeloma:A population-based study[J].J Bone Miner Res,2005,20(9):487-493.
  • 2Roodman GD,Choi SJ.MIP-1 alpha and myeloma bone disease[J].Cancer Treat Res,2004,118(9):83-100.
  • 3许多荣,罗绍凯,童秀珍,李娟.TNFR1/RANK嵌合体的构建及其在研究破骨细胞分化中的意义[J].中山大学学报(医学科学版),2007,28(4):378-382. 被引量:3
  • 4许多荣,罗绍凯,苏畅,方荸荠,黄珊,李娟.调节破骨细胞分化的RANK特异性cDNA片段的研究[J].中山大学学报(医学科学版),2009,30(1):1-5. 被引量:3
  • 5Alexandrakis MG,Passam FH,Malliaraki N,et al.Evaluation of bone disease in multiple myeloma:a correlation between biochemicak markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients[J].Clin Chim Acta,2002,325(1-2):51-57.
  • 6Mundy GR.Osteoporosis and inflammation[J].Nutr Rev,2007,65(12 Pt 2):S147-151.
  • 7Masahiro A,Kenji H,Javier W,et al.Role for macrophage inflammatory protein MIP-1αand MIP-1βin the development of osteolytic lensions in multiple myeloma[J].Blood,2002,100(6):2195-2202.
  • 8Yata K,Abe M,Matsumoto T,et al.Mechanisms for formation of myeloma bone disease[J].Clin Calcium,2008,18(4):438-446.
  • 9Tsubaki M,Kato C.Macrophage inflammatory protein-1alpha(MIP-1alpha)enhances a receptor activator of nuclear factor kappa B ligand(RANKL)expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways[J].Mol Cell Biochem,2007,304(1-2):53-60.
  • 10H an JH,Choi SJ,Kurihara N,et al.Macrophage inflammatory protein-1 alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappa B ligand[J].Blood,2001,97(9):3349-3353.

二级参考文献21

  • 1许多荣,余学清,方荸荠.甲状旁腺激素在体外对破骨细胞分化及骨重吸收能力的影响[J].中华肾脏病杂志,2005,21(4):186-190. 被引量:14
  • 2黄少慧,李娟,赵毅,张娟.补肾中药骨灵片对人成骨细胞功能和p38活化原蛋白激酶通路的影响[J].热带医学杂志,2007,7(5):418-420. 被引量:16
  • 3许多荣,罗绍凯,童秀珍,李娟.TNFR1/RANK嵌合体的构建及其在研究破骨细胞分化中的意义[J].中山大学学报(医学科学版),2007,28(4):378-382. 被引量:3
  • 4曹艳艳,李娟,杨春莉,黄少慧,吴湘慧,赵毅.骨灵片对骨质疏松大鼠血清OPG/RANKL、PICP和相关细胞因子的影响[J].热带医学杂志,2007,7(7):629-632. 被引量:9
  • 5Inoue J, Ishida T, Tsukamoto N, et al. Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling [J]. Exp Cell Res, 2000,254(1) : 14-24.
  • 6Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand [J]. Proc Natl Acad Sci USA, 1999,96(7): 3540-3545.
  • 7Darnay BG, Ni J, Moore PA, et al. Activation of NF- kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB- inducing kinase. Identification of a novel TRAF6 interaction motif [J]. J Biol Chem, 1999,274(12): 7724-7731.
  • 8Xu D, Shi Z, McDonnald J, et al. Development of a chimacric receptor approach to study signaling by tumour necrosis factor family members [J]. Biochem J, 2004,383 (4) : 219-225.
  • 9Mountazios G, Dimopoulos MA, Bamias A, et al. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor- kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton [J]. Acta Oncol, 2007,46(2) :221-229.
  • 10Boyce BF, Xing L. The RANKL/RANK/OPG pathway [J]. Curr Osteoporos Rep, 2007,5(3):98-104.

共引文献3

同被引文献26

  • 1Ortiz A,Lin SH.Osteolytic and osteoblastic bone metastases:two extremes of the same spectrum[J].Recent Results Cancer Res,2012,192(2):225-233.
  • 2Vallet S,Pozzi S,Patel K,et al.A novel role for CCL3(MIP-1α)in myeloma-induced bone disease via osteocalcin down-regulation and inhibition of osteoblast function[J].Leukemia,2011,25(7):1174-1181.
  • 3Qiang YW,Chen Y,Brown N,et al.Characterization of Wnt/beta-catenin signaling in osteoclasts in multiple myeloma[J].Br J Haematol,2010,148(5):726-738.
  • 4Brunetti G,Oranger A,Mori G,et al.Sclerostin is over expressed by plasma cells from multiple myeloma patients[J].Ann N Y Acad Sci,2011,12(37):19-23.
  • 5Chen Z,Orlowski RZ,Wang M,et al.Osteoblastic niche supports the growth of quiescent multiple myeloma cells[J].Blood,2014,123(14):2204-2208.
  • 6Roodman GD.Osteoblast function in myeloma[J].Bone,2011,48(1):135-140.
  • 7Zhou F,Meng S,Song H,et al.Dickkopf-1 is a key regulator of myeloma bone disease:opportunities and challenges for therapeutic intervention[J].Blood Rev,2013,27(6):261-267.
  • 8Kristensen IB,Christensen JH,Lyng MB,et al.Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma:only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease[J].Leuk Lymphoma,2014,55(4):911-919.
  • 9Tsirakis G,Roussou P,Pappa CA,et al.Increased serum levels of MIP-1 alpha correlate with bone disease and angiogenic cytokines in patients with multiple myeloma[J].Med Oncol,2014,31(1〉:778.
  • 10许兵,刘慧,许应星,吴岩,肖鲁伟,童培建.成骨细胞中经典Wnt/β-catenin通路研究进展[J].生命科学,2011,23(5):477-481. 被引量:25

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部